Recruit patients faster in the asia-pacific region
Asia remains one of the fastest growing regions for biotech-sponsored trials and there is a growing interest from US biotechs to expand their clinical development here. While there are many benefits in running clinical trials in Asia, sponsors can often face fragmented markets and heterogeneous regulatory pathways. This increases the need to partner with a regional CRO specialist who understands the regulatory nuances of each country to match with client-specific trial requirements.
Novotech relies on years of experience, in-country knowledge and real-life big data to identify and propose the best-performing sites and investigators for your study. Our experience span across numerous therapeutic areas and indications especially:
- Oncology CRO services, and Immuno-Oncology CRO services
- Infectious diseases and Vaccines CRO services
- Orphan and Rare diseases CRO services
Asia-Pacific is a preferred location for clinical studies because of lower trial density, large pools of patients, high number of active investigators, with efficient regulatory pathways.
Novotech has partnered with some of the leading medical institutions in the region. The Partnership Program is strategically designed to bring unparalleled access to quality investigators, key opinion leaders, and up to 4 billion patients for its international biotech clients.
Some words of Introduction from our Management
“We are seeing increased interest from US biotech in Asia-pacific, as sponsors are facing increased competition in the US and Europe for investigators, sites, and patients.
We've enjoyed exceptionally strong growth. But we remain very focused on our core mission, of being a full-service CRO, specializing in biotech sector sponsors conducting trials in the Asia-pacific region.
The countries in our region are very different, and a core part of our job is to match sponsor needs to country characteristics. For example, in Australia and New Zealand you will get some of the fastest start-up times in the world.
Australia has several financial advantages because of the R&D cash refund scheme. Across Asia you get access to billions often treatment naive patients in easy and accessible urban areas. All the big cities in Asia have expanding facilities and world recognized investigators.
Asia is a heterogenous environment with different cultures, languages, and regulatory environments. A core to our strategy is to have experienced local leadership and on-the-ground regulatory, and monitoring presence in each of the countries in which we operate. Our people have a deep understanding of their local environment and excellent English language capabilities.
Sometimes we are the regional provider working alongside global CROs and offering our expertise clinical and regulatory in the region. Other times we work alongside our strategic partners other like-minded US, and European CROs of a similar size with regions in these cases we work as a team, setting up a global project management structure and a unified set of systems and processes, to make sure there's consistency and quality across the world on global studies still getting to use the advantages of regional providers with core regional specialities."